PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...
Academic-community partnerships can reduce patient travel burdens while maintaining high-quality cancer care, as demonstrated by successful high-dose cytarabine consolidation delivery. A flow ...
Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 ...
SELLAS Life Sciences Group, Inc. has announced significant milestones in its clinical development of cancer therapies. An Independent Data Monitoring Committee will conduct an interim analysis of the ...
AML 3.0 by IDMERIT is redefining what modern anti money laundering software looks like - faster screening, smarter monitoring ...
Foghorn Therapeutics Inc. FHTX recently announced that the FDA has placed a full clinical hold on the phase I dose escalation study of pipeline candidate FHD-286 in relapsed and/or refractory acute ...
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 ...
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results